Hikma Pharmaceuticals (LON:HIK) Sets New 12-Month High – Should You Buy?

Hikma Pharmaceuticals PLC (LON:HIK) shares hit a new 52-week high on Thursday . The company traded as high as GBX 2,296 ($28.48) and last traded at GBX 2,294 ($28.46), with a volume of 311692 shares trading hands. The stock had previously closed at GBX 2,282 ($28.31).

Analyst Ratings Changes

Separately, Berenberg Bank increased their price target on Hikma Pharmaceuticals from GBX 2,400 ($29.77) to GBX 2,560 ($31.76) and gave the company a “buy” rating in a report on Wednesday, January 29th.

Hikma Pharmaceuticals Stock Down 0.4 %

The company has a debt-to-equity ratio of 55.48, a quick ratio of 1.27 and a current ratio of 1.66. The stock has a market cap of £5.07 billion, a PE ratio of 3,513.85, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company’s 50-day moving average price is GBX 2,044.67 and its 200 day moving average price is GBX 1,966.12.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.